AT412129B - Verfahren zur diagnose von nierenschädigungen im frühstadium durch messen der apoa-iv-menge in einer serum- oder plasmaprobe - Google Patents
Verfahren zur diagnose von nierenschädigungen im frühstadium durch messen der apoa-iv-menge in einer serum- oder plasmaprobe Download PDFInfo
- Publication number
- AT412129B AT412129B AT0116701A AT11672001A AT412129B AT 412129 B AT412129 B AT 412129B AT 0116701 A AT0116701 A AT 0116701A AT 11672001 A AT11672001 A AT 11672001A AT 412129 B AT412129 B AT 412129B
- Authority
- AT
- Austria
- Prior art keywords
- sep
- apoa
- serum
- kidney damage
- kidney
- Prior art date
Links
- 210000003734 kidney Anatomy 0.000 title claims description 78
- 230000006378 damage Effects 0.000 title claims description 62
- 210000002966 serum Anatomy 0.000 title claims description 51
- 238000000034 method Methods 0.000 title claims description 32
- 238000003745 diagnosis Methods 0.000 title claims description 8
- 101100055841 Danio rerio apoa1 gene Proteins 0.000 title 1
- 108010073614 apolipoprotein A-IV Proteins 0.000 claims description 170
- 102100037320 Apolipoprotein A-IV Human genes 0.000 claims description 164
- 230000003143 atherosclerotic effect Effects 0.000 claims description 32
- 208000029078 coronary artery disease Diseases 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 11
- 241000282414 Homo sapiens Species 0.000 claims description 10
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 4
- 206010037596 Pyelonephritis Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
- 210000004351 coronary vessel Anatomy 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 3
- 238000011088 calibration curve Methods 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 238000003748 differential diagnosis Methods 0.000 claims 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 42
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 33
- 230000003907 kidney function Effects 0.000 description 29
- 208000017169 kidney disease Diseases 0.000 description 22
- 229940109239 creatinine Drugs 0.000 description 21
- 201000001474 proteinuria Diseases 0.000 description 21
- 208000020832 chronic kidney disease Diseases 0.000 description 19
- 108010010234 HDL Lipoproteins Proteins 0.000 description 17
- 102000015779 HDL Lipoproteins Human genes 0.000 description 17
- 102000007592 Apolipoproteins Human genes 0.000 description 15
- 108010071619 Apolipoproteins Proteins 0.000 description 15
- 206010012601 diabetes mellitus Diseases 0.000 description 15
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 13
- 201000001320 Atherosclerosis Diseases 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 208000028208 end stage renal disease Diseases 0.000 description 11
- 201000000523 end stage renal failure Diseases 0.000 description 11
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 10
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 239000004202 carbamide Substances 0.000 description 10
- 238000001631 haemodialysis Methods 0.000 description 10
- 230000000322 hemodialysis Effects 0.000 description 10
- 241000282412 Homo Species 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 8
- 102000004895 Lipoproteins Human genes 0.000 description 7
- 108090001030 Lipoproteins Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 206010062237 Renal impairment Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 6
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
- 229930105110 Cyclosporin A Natural products 0.000 description 5
- 108010036949 Cyclosporine Proteins 0.000 description 5
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 5
- 238000008214 LDL Cholesterol Methods 0.000 description 5
- 108010033266 Lipoprotein(a) Proteins 0.000 description 5
- 208000001647 Renal Insufficiency Diseases 0.000 description 5
- 108010071390 Serum Albumin Proteins 0.000 description 5
- 102000007562 Serum Albumin Human genes 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229960001265 ciclosporin Drugs 0.000 description 5
- 229930182912 cyclosporin Natural products 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 201000006370 kidney failure Diseases 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 102000018619 Apolipoproteins A Human genes 0.000 description 4
- 108010027004 Apolipoproteins A Proteins 0.000 description 4
- 102000018616 Apolipoproteins B Human genes 0.000 description 4
- 108010027006 Apolipoproteins B Proteins 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 230000024924 glomerular filtration Effects 0.000 description 4
- 238000007477 logistic regression Methods 0.000 description 4
- 230000004141 reverse cholesterol transport Effects 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 108010012927 Apoprotein(a) Proteins 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000000885 nephron Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 101710095342 Apolipoprotein B Proteins 0.000 description 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010004103 Chylomicrons Proteins 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- -1 Lp (a) Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010027525 Microalbuminuria Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 2
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 2
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 2
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000004634 feeding behavior Effects 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000008604 lipoprotein metabolism Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 231100000857 poor renal function Toxicity 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 1
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 1
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102000043296 Lipoprotein lipases Human genes 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100022663 Retinal guanylyl cyclase 1 Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000037876 carotid Atherosclerosis Diseases 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- 239000002611 ionic contrast media Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019553 satiation Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000000365 steroidogenetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/106664—Blood serum or blood plasma standard or control
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0116701A AT412129B (de) | 2001-07-26 | 2001-07-26 | Verfahren zur diagnose von nierenschädigungen im frühstadium durch messen der apoa-iv-menge in einer serum- oder plasmaprobe |
| US10/485,039 US7842463B2 (en) | 2001-07-26 | 2002-07-23 | Method of diagnosing early stage renal impairment |
| PCT/AT2002/000219 WO2003010544A2 (fr) | 2001-07-26 | 2002-07-23 | Procede de diagnostic de lesions renales au stade precoce |
| AT02762152T ATE492816T1 (de) | 2001-07-26 | 2002-07-23 | Verfahren zur diagnose von nierenschädigungen im frühstadium |
| DE50214823T DE50214823D1 (de) | 2001-07-26 | 2002-07-23 | Verfahren zur diagnose von nierenschädigungen im frühstadium |
| AU2002328194A AU2002328194B2 (en) | 2001-07-26 | 2002-07-23 | Method for the diagnosis of kidney damage in the early stages |
| JP2003515863A JP4249612B2 (ja) | 2001-07-26 | 2002-07-23 | 初期腎機能障害の検査方法 |
| CA002454518A CA2454518A1 (fr) | 2001-07-26 | 2002-07-23 | Apoa-iv comme marqueur de diagnostic de trouble renal precoce |
| EP02762152A EP1410039B1 (fr) | 2001-07-26 | 2002-07-23 | Procede de diagnostic de lesions renales au stade precoce |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0116701A AT412129B (de) | 2001-07-26 | 2001-07-26 | Verfahren zur diagnose von nierenschädigungen im frühstadium durch messen der apoa-iv-menge in einer serum- oder plasmaprobe |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ATA11672001A ATA11672001A (de) | 2004-02-15 |
| AT412129B true AT412129B (de) | 2004-09-27 |
Family
ID=3686473
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT0116701A AT412129B (de) | 2001-07-26 | 2001-07-26 | Verfahren zur diagnose von nierenschädigungen im frühstadium durch messen der apoa-iv-menge in einer serum- oder plasmaprobe |
| AT02762152T ATE492816T1 (de) | 2001-07-26 | 2002-07-23 | Verfahren zur diagnose von nierenschädigungen im frühstadium |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02762152T ATE492816T1 (de) | 2001-07-26 | 2002-07-23 | Verfahren zur diagnose von nierenschädigungen im frühstadium |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7842463B2 (fr) |
| EP (1) | EP1410039B1 (fr) |
| JP (1) | JP4249612B2 (fr) |
| AT (2) | AT412129B (fr) |
| AU (1) | AU2002328194B2 (fr) |
| CA (1) | CA2454518A1 (fr) |
| DE (1) | DE50214823D1 (fr) |
| WO (1) | WO2003010544A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007028636A1 (fr) * | 2005-09-09 | 2007-03-15 | Medizinische Universität Innsbruck | Methode de prediction de la progression d'une maladie chronique des reins par le dosage de l'apolipoproteine a-iv |
| WO2019167874A1 (fr) | 2018-02-27 | 2019-09-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Anticorps monoclonal dirigé contre apoa4, procédé de dosage immunologique et kit de mesure |
-
2001
- 2001-07-26 AT AT0116701A patent/AT412129B/de not_active IP Right Cessation
-
2002
- 2002-07-23 CA CA002454518A patent/CA2454518A1/fr not_active Abandoned
- 2002-07-23 WO PCT/AT2002/000219 patent/WO2003010544A2/fr active Application Filing
- 2002-07-23 AU AU2002328194A patent/AU2002328194B2/en not_active Ceased
- 2002-07-23 AT AT02762152T patent/ATE492816T1/de active
- 2002-07-23 JP JP2003515863A patent/JP4249612B2/ja not_active Expired - Fee Related
- 2002-07-23 DE DE50214823T patent/DE50214823D1/de not_active Expired - Lifetime
- 2002-07-23 US US10/485,039 patent/US7842463B2/en active Active
- 2002-07-23 EP EP02762152A patent/EP1410039B1/fr not_active Expired - Lifetime
Non-Patent Citations (3)
| Title |
|---|
| M.SEISHIMA ET AL, CLINICA CHIMICA ACTA, BD. 167, 1987, S. 303-311 * |
| M.SEISHIMA ET AL, JOURNAL OF LIPID RESEARCH, BD. 33, 1992, S. 1441-1447 * |
| Z.A. MASSY ET AL., CLIN. NEPHROL., 55(2), FEB. 2001,S. 156-158 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2454518A1 (fr) | 2003-02-06 |
| WO2003010544A3 (fr) | 2003-09-12 |
| WO2003010544A8 (fr) | 2003-11-27 |
| US20040234989A1 (en) | 2004-11-25 |
| ATA11672001A (de) | 2004-02-15 |
| DE50214823D1 (de) | 2011-02-03 |
| AU2002328194B2 (en) | 2007-08-30 |
| EP1410039A2 (fr) | 2004-04-21 |
| US7842463B2 (en) | 2010-11-30 |
| JP4249612B2 (ja) | 2009-04-02 |
| EP1410039B1 (fr) | 2010-12-22 |
| ATE492816T1 (de) | 2011-01-15 |
| WO2003010544A2 (fr) | 2003-02-06 |
| JP2004536323A (ja) | 2004-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69937368T2 (de) | Nachweis von erkrankungen der nieren und behandlung | |
| DE69921668T2 (de) | Nachweis und bestimmung von stufen der coronaren arterienerkrankung | |
| Berg et al. | Kidney morphological changes in relation to long-term renal function and metabolic control in adolescents with IDDM | |
| WO2004090546A1 (fr) | Mise en evidence d'un peptide partiel proadrenomedulline a region moyenne dans des liquides biologiques, a des fins diagnostiques et dosages immunologiques utilises pour effectuer une mise en evidence de ce type | |
| Rudel et al. | Male–female variability in the dietary cholesterol-induced hyperlipoproteinemia of cynomolgus monkeys (Macaca fascicularis). | |
| DE202005020939U1 (de) | Kit zur Messung der Aktivierung neutrophiler Zellen | |
| EP1904082B1 (fr) | PROCÉDÉ POUR DÉTERMINER LA CONCENTRATION D'UNE FORME ADIPOCYTAIRE DE LA PROTÉINE DE LIAISON AUX ACIDES GRAS (A-FABP, FABP4, aP2) | |
| Attman et al. | Dyslipoproteinemia in diabetic renal failure | |
| DE60113976T2 (de) | Funktionaler nachweis von lipoprotein mit hoher dichte | |
| Srinivasan et al. | Black-white differences in cholesterol levels of serum high-density lipoprotein subclasses among children: the Bogalusa Heart Study. | |
| DE60317070T2 (de) | Verfahren zur diagnose von multipler sklerose | |
| DE60112949T2 (de) | Verfahren zum nachweis eines lipoprotein-akutphaseprotein-komplexes | |
| AT412129B (de) | Verfahren zur diagnose von nierenschädigungen im frühstadium durch messen der apoa-iv-menge in einer serum- oder plasmaprobe | |
| EP1104547B1 (fr) | Procede in vitro pour depister et diagnostiquer des syndromes coronariens aigus | |
| DE69911417T2 (de) | Verfahren zur diagnose von gefässerkrankungen und früher atheriosklerose | |
| Wang et al. | Monitoring nasal allergic inflammation by measuring the concentration of eosinophil cationic protein and eosinophils in nasal secretions | |
| Clodi et al. | Urinary excretion of apolipoprotein (a) fragments in type 1 diabetes mellitus patients | |
| Alaupovic et al. | Separation and identification of apo-B-containing lipoprotein particles in normolipidemic subjects and patients with hyperlipoproteinemias | |
| Adekoya et al. | Pattern of lipid profile in adult nephrotic syndrome patients in Nigeria | |
| Rahman et al. | Correlation of serum parathormone level with biochemical parameters in chronic renal failure | |
| EP1711831A1 (fr) | Procede pour le diagnostic de la septicemie par detection selective de la concentration de la superoxide dismutase 1 dans des echantillions biologiques | |
| EP1664789B1 (fr) | Procede pour diagnostiquer des maladies en identifiant une apolipoproteine c-i | |
| Jhuma et al. | Effects of laparoscopic cholecystectomy on apolipoproteins (ApoA1, ApoB100, ApoE) status in Bangladeshi patients with cholelithiasis | |
| DE102008022609B4 (de) | Verfahren zum Nachweis des Vorkommens von Nierensteinen und/oder Entzündungen der ableitenden Harnwege | |
| Abrams et al. | Normocholesterolemic dysbetalipoproteinemia with xanthomatosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM01 | Lapse because of not paying annual fees |
Effective date: 20120215 |